Ger­man ra­dio­phar­ma Ariceum un­veils ear­ly ef­fi­ca­cy sig­nal for lead as­set in neu­roen­docrine can­cers

Berlin-based Ariceum Ther­a­peu­tics has re­vealed pos­i­tive da­ta from a Phase I/II tri­al of its ra­dio­phar­ma­ceu­ti­cal ther­a­py, satoreotide, in neu­roen­docrine tu­mors, two years af­ter the biotech …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER